Angelini Pharma Appoints Sergio Marullo di Condojanni As CEO

KUALA LUMPUR, Jan 22 (Bernama) -- Angelini Pharma, part of the multinational privately owned industrial group Angelini Industries, has appointed Sergio Marullo di Condojanni as Chief Executive Officer (CEO).

Marullo di Condojanni, who has served as CEO of Angelini Industries since 2020, will retain that role while assuming leadership of the pharmaceutical division to ensure cohesive strategy execution across the group.

Angelini Holding Chair and majority shareholder, Thea Paola Angelini said the appointment is aimed at simplifying decision-making and strengthening the group’s pharmaceutical business.

“This strategic choice will enable us to be closer to market needs and, above all, to patients, by delivering greater efficiency, agility, faster decision-making, and flexibility,” she said in a statement.

The appointment forms part of Angelini Industries’ multi-year effort to strengthen its corporate governance and operating model, reinforcing pharmaceutical healthcare as a core pillar of its long-term growth strategy alongside industrial technology.

In his dual role, Marullo di Condojanni will directly spearhead strategy implementation within the healthcare division, focusing on expanding its leadership in brain health, particularly in rare neurological diseases, while continuing to build on its consumer healthcare portfolio.

He will also prioritise the expansion of Angelini Pharma’s global footprint, including potential acquisitions to strengthen its pipeline, while maintaining sustained investment in research, development and manufacturing operations in Italy.

Angelini Pharma has significantly strengthened its pipeline in recent years, diversifying into innovative therapeutic modalities, including small molecules, biologics and antisense oligonucleotides, supported by a series of strategic agreements and partnerships.

-- BERNAMA